New driver mutations in non-small-cell lung cancer.

By William Pao, N. Girard. The Lancet Oncology, 2011

1,202 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/bf0cf4dc20db17f6db0c0503d02c5a192d5ab7c4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. B. Chan
2. B. Hughes

In Pulmonary and Respiratory Medicine

1. B. Hughes
2. B. Chan

Citations in the corpus

• Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma (2016, background): “Meanwhile, mutations in tumor suppressor genes TP53 and STK11 are also common in lung 96 adenocarcinoma and frequently co-occur with KRAS mutations(13-15).”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “Sequencing of the human genome has permitted more efficient identification of epigenetic mutations, tumoursuppressor-gene inactivation as well as oncogene driver mutations that are potential targets for therapy (3-8).”
• Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs (2014, neutral): “ERBB2 (formerly HER2) 23 (2) [2-4] 19 (3) [2-4] 11 (48)”